Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

NCT05669599

Amgen · Phase 2 · Completed · Enrollment 592

NCT05669599

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Cohort A: Maridebart Cafraglutiden/rn/rn/rn/r
Cohort A: Placebon/rn/rn/rn/r
Cohort B: Maridebart Cafraglutiden/rn/rn/rn/r
Cohort B: Placebon/rn/rn/rn/r

Not shown

  • Cohort A: Maridebart Cafraglutide: endpoint not reported
  • Cohort A: Placebo: endpoint not reported
  • Cohort B: Maridebart Cafraglutide: endpoint not reported
  • Cohort B: Placebo: endpoint not reported